News
-
04.16.26 Company Updates
Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors
Achieve Names Two New Exemplary Healthcare Leaders to its Board of Directors. New Leadership and Financing, up to $354 Million ($180 Million Upfront and $174 Million Dependent on the Exercise of Milestone Warrants), Strengthen Achieve’s Position to Execute Development and Launch of Cytisinicline, if Approved, as the First New Treatment for Nicotine Dependence in Two…
-
04.15.26 Company Updates
Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions
Adare Partnership Provides Supply Chain Redundancy and U.S.-based Manufacturing Capability. Company Reiterates Guidance – If Approved, Cytisinicline Commercial Launch Expected in First Half of 2027. SEATTLE and VANCOUVER, British Columbia, April 15, 2026 (GLOBENEWSWIRE)– Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and…
-
01.12.26 Company Updates
Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer
Experienced medical executive advances to permanent role following successful leadership as Interim CMO. SEATTLE and VANCOUVER, British Columbia, January 12, 2026 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced that it has…
-
10.20.25 Company Updates
Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer
New life sciences executive brings more than 25 years of legal expertise spanning clinical and commercial stage biopharmaceutical companies. SEATTLE and VANCOUVER, British Columbia, October 20, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence…
-
09.18.25 Company Updates
Achieve Life Sciences Promotes Craig Donnelly to Chief Operations Officer
Donnelly brings more than 25 years of biopharmaceutical expertise in CMC and regulatory operations. SEATTLE and VANCOUVER, British Columbia, September 18, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced…